1. Signaling Pathways
  2. GPCR/G Protein
  3. Platelet-activating Factor Receptor (PAFR)

Platelet-activating Factor Receptor (PAFR)

The platelet-activating factor receptor (PAFR) is a G-protein-coupled receptor involved in both normal physiological and numerous pathophysiological processes. PAFR responds to platelet-activating factor (PAF), a phospholipid mediator of cell-to-cell communication that exhibits diverse physiological effects. Stimulation of the PAFR via binding of platelet-activating factor (PAF) elicits diverse and potent biological activities and plays a profound role in acute inflammation, allergic disorders, endotoxic shock, and anaphylaxis. PAF is a potent and versatile mediator of inflammation that is produced by numerous cell types and tissues, and particularly by leukocytes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-141612
    Pyrrolidino PAF C-16
    Activator
    Pyrrolidino PAF C-16 is a platelet activating factor ( PAF ) analogue that has hypohematic effects.
    Pyrrolidino PAF C-16
  • HY-101654
    Rocepafant
    Antagonist
    Rocepafant (BN 50730) is a specific platelet activating factor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research.
    Rocepafant
  • HY-105198
    Lexipafant
    Lexipafant is a platelet-activating factor (PAF) antagonist that inhibits the inflammatory response and is used in the research of acute pancreatitis.
    Lexipafant
  • HY-121394
    L-659,989
    Agonist
    L-659,989 is an orally active, extremely potent, selective and competitive platelet activating factor (PAF) receptor antagonist.
    L-659,989
  • HY-N19876
    WF-5239
    Inhibitor
    WF-5239 is a fungal metabolite can be found in Aspergillus fumigatus Fresenius. WF-5239 potently inhibits platelet aggregation. WF-5239 can be used for the research of pulmonary thrombosis.
    WF-5239
  • HY-106899A
    (rel)-MK 287
    Control
    (rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis.
    (rel)-MK 287
  • HY-10164
    E-​6123
    E-6123 is a platelet-activating factor (PAF) receptor antagonist.
    E-​6123
  • HY-177598
    F-0401
    Antagonist
    F-0401 is a calcium antagonist with platelet-activating factor receptor (PAFR) antagonistic action. F-0401 can be used for the research of neurological disease, such as stroke.
    F-0401
  • HY-121007
    Bepafant
    Antagonist
    Bepafant (Web2170) is a platelet-activating factor (PAF) antagonist that protects against anaphylactic lethality in active and passive anaphylaxis models in mice and guinea pigs in a dose-dependent manner and attenuates bronchoconstriction and blood pressure changes in anaphylaxis.
    Bepafant
  • HY-101675
    Setipafant
    Setipafant is a platelet-activating factor (PAF) antagonist.
    Setipafant
  • HY-106833A
    SDZ-62-434
    Antagonist
    SDZ-62-434 is a platelet-activating factor (PAF) antagonist. SDZ-62-434 has antiproliferative activity in human solid and haematological malignancies.
    SDZ-62-434
  • HY-118019
    Scandenolide
    Scandenolide is a sesquiterpene lactone that can be found in Philippines medicinal plant Mikania cordata. Scandenolide inhibits leukotriene and platelet activating factor synthesis in leukocytes.
    Scandenolide
  • HY-126551
    Butenoyl-PAF
    Agonist
    Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.
    Butenoyl-PAF
  • HY-167719
    Dersalazine
    Inhibitor
    Dersalazine (UR-12746 free base) is an inhibitor of platelet-activating factor, exhibiting intestinal anti-inflammatory activity and potential efficacy in treating ulcerative colitis.
    Dersalazine
  • HY-123399
    Ro 19-1400
    Antagonist
    Ro 19-1400 is a platelet-activating factor antagonist that directly inhibits immunoglobulin E-dependent mediator release.
    Ro 19-1400
  • HY-N1620
    1-Cinnamoylpyrrolidine
    Inhibitor
    1-Cinnamoylpyrrolidine (Compound 3), a crude extract prepared from Piper caninum, is a DNA strand scission agent, induces the relaxation of supercoiled pBR322 plasmid DNA. 1-Cinnamoylpyrrolidine (Compound 4) inhibits platelet aggregation induced by PAF with an IC50 of 37.3 μM.
    1-Cinnamoylpyrrolidine
  • HY-124887
    L 651142
    Antagonist
    L 651142 is a weak platelet activating factor (PAF) receptor antagonist. L 651142 inhibits the binding of [3H]PAF to rabbit platelet, human platelet or human lung membranes with Kis of 0.839 μM, 1.82 μM, 3.64 μM, respectively.
    L 651142
  • HY-106038
    Acopafant
    Antagonist
    Acopafant (Dacopafant; RP 55778) is a potent platelet-activating factor antagonist. Acopafant inhibits the induction of human immunodeficiency virus (HIV) expression in chronically infected cells. Acopafant has the potential for the research of HIV infection.
    Acopafant
  • HY-125309
    ABT-299
    Antagonist
    ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite.
    ABT-299
  • HY-106062
    CV 3988
    Inhibitor
    CV 3988 is a specific inhibitor of platelet-activating factor (PAF).
    CV 3988
Cat. No. Product Name / Synonyms Application Reactivity